Tyler Goff, MD
Ophthalmology · Metairie, LANPI 1881115665
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,692 of the $7,441 with a category attached, or 76.5%. 21 manufacturers reported payments, led by Biotissue Holdings Inc. at 29.3% of the total. Reporting peaked in 2024 at $3,097 and has fallen 63.8% since, to $1,121 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $40.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Alcon$1K
- Glaukos Corporation$729
- Johnson & Johnson Surgical Vision, Inc.$524
- Mallinckrodt Hospital Products Inc.$440
- AbbVie$369
- plus $2K from 15 others
What the payments were for
- Travel & lodging$1,74924%
- Food & beverage$5,69276%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 20 | $2,181 |
| Alcon | 50 | $1,426 |
| Glaukos Corporation | 15 | $729 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $524 |
| Mallinckrodt Hospital Products Inc. | 14 | $440 |
| AbbVie(2 entities) | 7 | $369 |
| Rxsight Inc | 3 | $272 |
| Tarsus Pharmaceuticals, Inc. | 15 | $243 |
| Oyster Point Pharma, Inc. | 9 | $235 |
| Sight Sciences, Inc. | 10 | $213 |
| Bausch & Lomb Americas Inc. | 11 | $205 |
| Sun Pharmaceutical Industries Inc. | 5 | $201 |
| Dompe US, Inc. | 4 | $111 |
| Novartis | 2 | $80 |
| Ocular Therapeutix, Inc. | 4 | $65 |
| Harrow Eye, LLC | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $31 |
| Amgen | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| NEW World Medical,inc. | 1 | $17 |
| Coopervision Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon PanOptix Pro$263
- Clareon$262
- KXL System$261
- RXSIGHT CONTACT LENS$255
- RXSIGHT INJECTOR CARTRIDGE$255
- RXSIGHT INJECTOR HANDPIECE$255
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$255
- LIGHT ADJUSTABLE LENS (LAL)$255
- Tecnis IOL$229
- KXL1B-CE-marked KXLsystem$143
- Centurion$133
- Hydrus Microstent$125
- Photrexa$117
- ACTHAR$114
- CEQUA$113
- OZURDEX$109
How this compares
$7,441 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 26 | $1,079,886 |
| RestasisCyclosporine | 54 | $46,520 |
| XdemvyLotilaner | 22 | $42,192 |
| XiidraLifitegrast | 22 | $21,677 |
| MieboPerfluorohexyloctane/Pf | 19 | $19,697 |
| TyrvayaVarenicline Tartrate | 24 | $16,001 |
| Prednisolone Acetate | 395 | $13,749 |
| CequaCyclosporine | 12 | $12,481 |
| MoxifloxacinMoxifloxacin Hcl | 401 | $9,676 |
| LumiganBimatoprost | 21 | $5,492 |
| ProlensaBromfenac Sodium | 13 | $4,434 |
| ValacyclovirValacyclovir Hcl | 59 | $3,119 |
| Alphagan PBrimonidine Tartrate | 14 | $2,647 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 71 | $991 |
| Ketorolac Tromethamine | 36 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $111 | $1,079,88626 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $369 | $54,65989 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $243 | $42,19222 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $205 | $41,37441 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $235 | $16,00124 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $201 | $12,48112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Metairie
- Ethan SternMetairie$16K
- John FrisbeeMetairie$14K
- Benjamin GuidryMetairie$9K
- Scott LanouxMetairie$8K
- John BoyleMetairie$7K
- Nicholas FrisardMetairie$7K
- Brandon DavisMetairie$7K
- Henry HaleyMetairie$7K
- Owen LacourMetairie$6K
- Joshua GroetschMetairie$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.